PatientsVille.com
Hypothyroidism | Preconceptional Thyroid Screening and Childhood Nerocognitive Function
Hypothyroidism research study
What is the primary objective of this study?
To assess the effect of universal preconception hypothyroidism for maternal pregnancy outcome, and 0-3yrs offspring neurocognitive ability and IQ score.
Who is eligible to participate?
Inclusion Criteria: 1. Preconceptional group:TSH ≥ 97.5%th and/or FT4 ≤ 2.5%th 2. age: 18-55 3. those who can obey the rules of this study and assign the consent Exclusion Criteria: 1. age: less than 18 or more than 55 2. multiple pregnancy 3. thyroid tumor disease history 4. those who cannot obey the rules of this study
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Hypothyroidism
Study Interventions
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Procedure:levothyroxineWomen with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks.
Study Arms
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
preconceptionParticipants will be included according to their first outpatient visiting time. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
early conceptionParticipants will be included according to their first outpatient visiting time before 15+6 gestational week. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
late conceptionParticipants will be included according to their first outpatient visiting time after 16 gestational week. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
Study Status
Unknown status
Start Date: January 2011
Completed Date: December 2015
Phase: N/A
Type: Interventional
Design:
Primary Outcome: Offspring neurocognitive assessment at 0-3 yrs
Secondary Outcome: Incidence of neonatal hypothyroid and complications
Study sponsors, principal investigator, and references
Principal Investigator: Xiaotian Li, MD, PhD
Lead Sponsor: Fudan University
Collaborator: Shanghai Municipal Science and Technology Commission
More information:https://clinicaltrials.gov/show/NCT01744743
